Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEIL E FAULKNER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417165739
CMS profile
336230
Location
TIPTON, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,034.66

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,890.31 191
Education $144.35 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–194 of 194 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEIL E FAULKNER

NPI 1417165739 · CMS profile ID 336230

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TIPTON, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–194 of 194 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417165739?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEIL E FAULKNER, NPI 1417165739, CMS profile ID 336230. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–194 of 194 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417165739?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NEIL E FAULKNER, NPI 1417165739, CMS profile ID 336230. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–194 of 194 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417165739?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NEIL E FAULKNER, NPI 1417165739, CMS profile ID 336230, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–194 of 194 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417165739?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $3,034.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–194 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $10.1903/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681285929 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.4903/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628440083 CMS
Merck Sharp & Dohme Corporation $4.7803/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695882081 CMS
Merck Sharp & Dohme Corporation $10.9803/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695313963 CMS
Novartis Pharmaceuticals Corporation $12.5403/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660135691 CMS
Genentech USA, Inc. $3.2802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681266229 CMS
Pharmacyclics LLC, An AbbVie Company $13.9102/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665699935 CMS
E.R. Squibb & Sons, L.L.C. $2.5002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285285 CMS
Agios Pharmaceuticals, Inc. $11.3902/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701353767 CMS
E.R. Squibb & Sons, L.L.C. $15.7602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285305 CMS
Amgen Inc. $17.7002/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662823971 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697386273 CMS
Merck Sharp & Dohme Corporation $11.4402/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695280512 CMS
Merck Sharp & Dohme Corporation $6.1702/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695307310 CMS
JAZZ PHARMACEUTICALS INC. $20.1002/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684179063 CMS
E.R. Squibb & Sons, L.L.C. $8.3402/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285283 CMS
PFIZER INC. $13.0802/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671896341 CMS
Lilly USA, LLC $32.7602/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658049331 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.1302/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697386263 CMS
E.R. Squibb & Sons, L.L.C. $11.5002/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285281 CMS
Celgene Corporation $13.9602/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672732546 CMS
Amgen Inc. $22.1102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662823957 CMS
E.R. Squibb & Sons, L.L.C. $11.1202/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285279 CMS
Merck Sharp & Dohme Corporation $13.0002/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695285663 CMS
Amgen Inc. $13.3202/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662823954 CMS
Genentech USA, Inc. $15.3802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681280741 CMS
Novartis Pharmaceuticals Corporation $24.8002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660135725 CMS
E.R. Squibb & Sons, L.L.C. $11.5202/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285277 CMS
GENZYME CORPORATION $19.1201/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693933873 CMS
Merck Sharp & Dohme Corporation $6.7701/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695226539 CMS
Merck Sharp & Dohme Corporation $10.9001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695243339 CMS
Incyte Corporation $11.4701/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666240877 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.4901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700329195 CMS
Exelixis Inc. $12.6701/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686547449 CMS
Celgene Corporation $20.2501/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672851259 CMS
Merck Sharp & Dohme Corporation $10.9501/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695219921 CMS
EISAI INC. $17.6501/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696999423 CMS
E.R. Squibb & Sons, L.L.C. $12.8101/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651285275 CMS
Regeneron Healthcare Solutions, Inc. $16.0001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673376163 CMS
Merck Sharp & Dohme Corporation $12.2001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695207097 CMS
Genentech USA, Inc. $13.9101/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681168407 CMS
Lilly USA, LLC $15.4301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658038957 CMS
Genentech USA, Inc. $10.2601/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681308677 CMS
Merck Sharp & Dohme Corporation $9.9301/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695258471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,034.66 194
PY2020 $853.66 58
PY2021 $977.22 61
PY2022 $1,853.04 95
PY2023 $2,607.10 136
PY2024 $2,750.34 123
PY2025 $2,666.60 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $209.54 1
PY2025 Principal investigator $36,226.04 22
PY2024 Recipient $1,559.34 7
PY2024 Principal investigator $80,248.80 19
PY2023 Recipient $924.11 2
PY2023 Principal investigator $149,552.52 2
PY2022 Principal investigator $255,220.85 13
PY2021 Principal investigator $104,052.91 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.50 12/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/12/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184140331
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1235999744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,125.00 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,437.50 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184140031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 06/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 06/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,437.50 06/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,125.00 06/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 05/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,109.30 04/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,408.50 04/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,400.85 04/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,615.90 04/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,434.00 04/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184139423
Recipient Regeneron Pharmaceuticals, Inc. $209.54 03/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184117437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 01/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184139371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 01/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184139365